Skip to content

Research of Molecular and Metabolic Markers in Oligodendrogliomas Comparatively to Other Brain Tumours

Research of Molecular and Metabolic Diagnostic Markers in Oligodendrogliomas A and B Comparatively.

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00213876
Enrollment
189
Registered
2005-09-21
Start date
2004-02-29
Completion date
2011-08-31
Last updated
2011-08-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Oligodendrogliomas

Keywords

Brain tumours, oligodendrogliomas, allelotyping, SAGE, Presence of molecular abnormalities statistically linked to survival or response to chemotherapy

Brief summary

At present, diagnosis of oligodendroglioma is made on histological and radiographic criteria in the French Mayo-Ste Anne classification. The less frequent grade A oligodendrogliomas are characterized by no vascular contrast on RMN evaluation comparatively to grade B forms. This benign histological subtype relapses in few cases with a more aggressive histology. To determine these relapsed cases at diagnosis, a collection of tumour begun in February 2004. Then, our study was designed to identify diagnostic molecular and metabolic markers that could eventually be used as a signature characterising grade A versus grade B oligodendrogliomas. The molecular analysis will use genomic techniques like allelotyping study, quantitative real-time PCR, gene sequencing , serial analysis of genomic expression and immunohistochemistry, since the metabolic study will be the spectroscopic examination of in vivo tumour. This study will include paediatric and adult patients followed for oligodendrogliomas, medulloblastomas and gliomas to compare the different tumour signatures. All these results will be correlated to survival and clinical features.

Interventions

None listed

Sponsors

University Hospital, Strasbourg, France
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
1 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Paediatric and adult patients (\> 1 year of age) * Patient with oligodendroglioma or medulloblastoma or glioma * Possibility of 3 year follow-up * Patient consent obtained

Exclusion criteria

\-

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026